5145|10000|Public
5|$|Since {{treatment}} options for relapsed AML are so limited, palliative care or enrollment in <b>a</b> <b>clinical</b> <b>trial</b> may be offered.|$|E
5|$|In <b>a</b> <b>clinical</b> <b>trial</b> of 286 subjects, 53.2% of the 141 given {{immediate-release}} metformin (as {{opposed to}} placebo) reported diarrhea, versus 11.7% for placebo, and 25.5% reported nausea/vomiting, versus 8.3% {{for those on}} placebo.|$|E
5|$|Professional {{guidelines}} in the UK recommend {{that patients with}} VA dissection should be enrolled in <b>a</b> <b>clinical</b> <b>trial</b> comparing aspirin and anticoagulation if possible. American guidelines state that the benefit of anticoagulation is not currently established.|$|E
2500|$|<b>A</b> pragmatic <b>clinical</b> <b>trial</b> (PCT), {{sometimes}} called <b>a</b> practical <b>clinical</b> <b>trial</b> (PCT), ...|$|R
50|$|<b>A</b> <b>clinical</b> <b>trials</b> {{unit was}} set up in 1994 with 3 members of staff which has now {{expanded}} to a staff of 34. More than 9,700 patients have been recruited to take part in <b>a</b> variety of <b>clinical</b> <b>trials.</b>|$|R
5000|$|The NCI Experimental Therapeutics <b>Clinical</b> <b>Trials</b> Network (ETCTN) is <b>a</b> <b>clinical</b> <b>trials</b> {{network that}} evaluates {{innovative}} cancer treatments using a coordinated, collaborative, and inclusive team based approach to early phase experimental therapeutic <b>clinical</b> <b>trials.</b>|$|R
5|$|Similarly, the {{designed}} antioxidant NXY-059 exhibited efficacy {{in animal}} models, {{but failed to}} improve stroke outcomes in <b>a</b> <b>clinical</b> <b>trial.</b> As of November 2014, other antioxidants are being studied as potential neuroprotectants.|$|E
5|$|Anticonvulsants {{suppress}} epileptic seizures, {{but they}} neither cure nor prevent {{the development of}} seizure susceptibility. The development of epilepsy (epileptogenesis) {{is a process that}} is poorly understood. A few anticonvulsants (valproate, levetiracetam and benzodiazepines) have shown antiepileptogenic properties in animal models of epileptogenesis. However, no anticonvulsant has ever achieved this in <b>a</b> <b>clinical</b> <b>trial</b> in humans. The ketogenic diet has been found to have antiepileptogenic properties in rats.|$|E
5|$|The {{death of}} his father due to heart {{problems}} at the age of 49 had a lasting effect on Henderson. He was conscious of his own health, and survived a blockage in his own heart that was discovered in 2004. He was diagnosed with chronic lymphocytic leukemia in 2009. The disease prevented him from attending 40th anniversary celebrations of the Summit Series in Moscow, but he was responding well to experimental treatment as part of <b>a</b> <b>clinical</b> <b>trial</b> he participated in into 2013.|$|E
30|$|It {{could be}} {{administered}} to potential trial participants {{to identify those}} whose trial perceptions indicate that they could benefit from participating in <b>a</b> <b>clinical</b> <b>trials</b> education program. Those who score low on the ARTQ may benefit the most from <b>a</b> cancer <b>clinical</b> <b>trial</b> education intervention to enhance their perceptions of trials and to potentially increase rates of <b>clinical</b> <b>trial</b> enrollment. Alternatively, the education program and the ARTQ could be incorporated into standard trial recruitment procedures.|$|R
5000|$|The NCI National <b>Clinical</b> <b>Trials</b> Network (NCTN) is <b>a</b> <b>clinical</b> <b>trials</b> {{research}} {{network that}} provides an infrastructure for NCI treatment, screening and diagnosis trials. The NCTN infrastructure allows investigators to begin <b>clinical</b> <b>trials</b> quicker, reach conclusions faster and offer patients studies that incorporate precision medicine at over 3,000 clinical sites.|$|R
50|$|Celina Caesar-Chavannes, the {{president}} of ReSolve Research Solutions Inc., <b>a</b> <b>clinical</b> <b>trials</b> management service she co-founded {{with her husband in}} 2004, was acclaimed as the Liberal nominee on July 17, 2014.|$|R
25|$|Allopregnanolone {{is being}} studied in <b>a</b> <b>clinical</b> <b>trial</b> by the Mayo Clinic to treat super-resistant status epilepticus.|$|E
25|$|In February Kite Pharma {{announced}} {{results from}} <b>a</b> <b>clinical</b> <b>trial</b> of CAR-T cells in around {{a hundred people}} with advanced Non-Hodgkin lymphoma.|$|E
25|$|In 2009, Roche began {{recruiting}} in Russia for <b>a</b> <b>clinical</b> <b>trial</b> of Xenical in obese teenagers {{between the}} ages of 12 and 14.|$|E
50|$|With {{new drug}} therapies {{emerging}} rapidly, the CGD Center has established <b>a</b> <b>clinical</b> <b>trials</b> program {{to design and}} implement tests of experimental agents and allow patients access to therapies not yet widely available.|$|R
5000|$|TrialConnect, <b>a</b> free <b>clinical</b> <b>trial</b> {{matching}} service (http://www.abtatrialconnect.org).|$|R
50|$|May 2011: Solithromycin is in <b>a</b> Phase 2 <b>clinical</b> <b>trial</b> {{for serious}} community-acquired {{bacterial}} pneumonia (CABP) and in <b>a</b> Phase 1 <b>clinical</b> <b>trial</b> with <b>an</b> intravenous formulation.|$|R
25|$|Japan begins <b>a</b> <b>clinical</b> <b>trial</b> of {{stem cells}} {{harvested}} from patients' own bodies. The stem cells {{will be used to}} treat age-related macular degeneration.|$|E
25|$|<b>A</b> <b>clinical</b> <b>trial</b> of {{patients}} taking the benzodiazepine alprazolam for {{as short as}} eight weeks triggered protracted symptoms of memory deficits which were still present up to eight weeks after cessation of alprazolam.|$|E
25|$|In April 2011, the National Institutes of Health (NIH), in {{collaboration}} with the Therapeutics for Rare and Neglected Diseases Program (TRND), announced they were developing <b>a</b> <b>clinical</b> <b>trial</b> utilizing cyclodextrin for Niemann–Pick type C patients.|$|E
5000|$|... 2012: {{completed}} <b>a</b> phase-1 <b>clinical</b> <b>trial</b> for s.c. injection dosage form.|$|R
5000|$|... 2003: {{completed}} <b>a</b> phase-1a <b>clinical</b> <b>trial</b> for i.v. infusion dosage form.|$|R
5000|$|AllTrials (sometimes called All Trials or AllTrials.net) is {{a project}} advocating that {{clinical}} research adopt the principles of open research. The project summarizes itself as [...] "All trials registered, all results reported": that is, all <b>clinical</b> <b>trials</b> should be listed in <b>a</b> <b>clinical</b> <b>trials</b> registry, and their results should always be shared as open data.|$|R
25|$|For {{the first}} time in the United States, a {{bioengineered}} blood vessel is transplanted into a patient's arm. The patient, a man with end-stage kidney disease, is part of <b>a</b> <b>clinical</b> <b>trial</b> of laboratory-grown veins.|$|E
25|$|In 2016 the United States Food and Drug Administration (FDA) {{approved}} <b>a</b> <b>clinical</b> <b>trial</b> {{in which}} CRISPR {{would be used}} to alter T cells extracted from people with different kinds of cancer and then administer those engineered T cells back to the same people.|$|E
25|$|In 1998, <b>a</b> <b>clinical</b> <b>trial</b> {{demonstrated}} {{the effectiveness of}} intravenous pamidronate, a bisphosphonate which had previously been used in adults to treat osteoporosis. In severe OI, pamidronate reduced bone pain, prevented new vertebral fractures, reshaped previously fractured vertebral bodies, and {{reduced the number of}} long-bone fractures.|$|E
40|$|<b>Clinical</b> <b>trials</b> are {{essential}} in advancing our knowledge {{and treatment of}} patients with respiratory disease. Conducting well-designed clinical studies which accurately and reliably answer important clinical questions is challenging. The expertise required to deliver such studies is increasingly concentrated in <b>clinical</b> <b>trials</b> units. This article will describe some of the challenges associated with clinical studies and the methods and personnel involved in <b>a</b> <b>clinical</b> <b>trials</b> unit...|$|R
5000|$|Provided {{for federal}} support for <b>a</b> {{national}} <b>clinical</b> <b>trials</b> network for SMA.|$|R
5000|$|... 2015: {{initiated}} <b>a</b> phase-3 <b>clinical</b> <b>trial</b> for i.v. infusion {{dosage form}} (on-going).|$|R
25|$|<b>A</b> <b>clinical</b> <b>trial</b> {{conducted}} at Harvard Medical School {{in the mid-1990s}} demonstrated {{that a majority of}} persons with non‑psychotic unipolar depression who were refractory to conventional antidepressants and electroconvulsive therapy could be successfully treated with buprenorphine. Clinical depression is currently not an approved indication for the use of any opioid.|$|E
25|$|Buprenorphine {{has been}} used in the {{treatment}} of the neonatal abstinence syndrome, a condition in which newborns exposed to opioids during pregnancy demonstrate signs of withdrawal. Use currently is limited to infants enrolled in <b>a</b> <b>clinical</b> <b>trial</b> conducted under an FDA approved investigational new drug (IND) application. An ethanolic formulation used in neonates is stable at room temperature for at least 30 days.|$|E
25|$|A novel miRNA-profiling-based {{screening}} assay {{for the detection}} of early-stage colorectal cancer is undergoing <b>a</b> <b>clinical</b> <b>trial.</b> Early results showed that blood plasma samples collected from patients with early, resectable (Stage II) colorectal cancer could be distinguished from those of sex-and age-matched healthy volunteers. Sufficient selectivity and specificity could be achieved using small (less than 1 mL) samples of blood.|$|E
40|$|Abstract Information on {{blinding}} {{is part of}} {{the data}} that should be provided upon registration of <b>a</b> <b>trial</b> at <b>a</b> <b>clinical</b> <b>trials</b> registry. Reporting of blinding is often absent or of low quality in published articles of <b>clinical</b> <b>trials.</b> This study researched the presence and quality of information on blinding in registered records of <b>clinical</b> <b>trials</b> and highlights the important role of data-recording formats at <b>clinical</b> <b>trial</b> registries in ensuring high-quality registration. </p...|$|R
25|$|The Alzheimer's drug Gammagard {{fails to}} produce results in <b>a</b> {{large-scale}} <b>clinical</b> <b>trial.</b>|$|R
50|$|The Food and Drug Administration {{mandates}} <b>a</b> 3 phase <b>clinical</b> <b>trial</b> {{testing that}} tests for {{side effects and}} the effectiveness of the drug with <b>a</b> single phase <b>clinical</b> <b>trial</b> costing upwards of $100 million.|$|R
